Malignant ascites indicate the presence of malignant cells in the peritoneal cavity. The most common malignancies linked with the development of malignant ascites are cancers of the ovary, colon or rectum, breast, lung, liver, lungs, and lymphoma. The survival rate of such patients is poor; however, appropriate treatment modalities can improve the quality of life. Traditional therapies for malignant ascites include paracentesis, shunting, drugs such as spironolactone and catumaxomab, and chemotherapy. With the advent of monoclonal antibodies for the treatment of malignancies, catumaxomab is becoming increasingly preferred in the palliative care of malignant ascites.
The report titled “Global Malignant Ascites Market: Growth, Share, Opportunities, and Competitive Analysis, 2016–2024” offers strategic insights into the overall malignant ascites market, along with the market size and estimates for the duration of 2016 to 2024. The said research study covers an in-depth analysis of multiple market segments based on the type of treatment, type of application, and different geographical regions. The treatment type segment studied for analyzing the overall malignant ascites market is majorly segmented into therapeutic treatment and surgical treatment. On the basis of type of application, the malignant ascites market is segmented into ovarian cancer, breast cancer, gastrointestinal cancer, colorectal cancer, carcinoma of unknown primary, and other cancers.
In order to help strategic decision-makers, the report also includes competitive profiling of the leading players in the malignant ascites market, attractive investment propositions, and market positioning of key manufacturers. Other in-depth analysis provided in the report includes:
Geographically, the global malignant ascites market is studied for the following regional markets:
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
The market size and forecast for these regional and country-level markets are presented in this study for the period 2013–2023. Market growth rates for the forecast period 2016–2023 are also included in this report, considering 2015 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global malignant ascites market. Tools such as the market positioning of key players and attractive investment propositions provide the readers with insights into the competitive scenario of the global malignant ascites market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global malignant ascites market. In-depth competitive environment analysis and historical years (2013 and 2014) of market size data are also provided in the report.
Thus, the research study provides a holistic view of the global malignant ascites market, offering market size and estimates for the period from 2016 to 2023, keeping in mind the above-mentioned factors.
Based on the type of application, the global malignant ascites treatment market is segmented as follows:
- Ovarian Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Colorectal Cancer
- carcinoma of unknown primary
- Other Cancers
In 2015, ovarian cancer was observed as the largest application segment. A study published by the National Cancer Institute also suggests that approximately 1.3% of women will be diagnosed with ovarian cancer at some point in their lives. The key factors assisting the market growth of this segment are the high prevalence of ovarian cancer and the difficulty in early diagnosis, which increases the complexities associated with malignant ascites. It is evident that malignant ascites play a key role in ovarian tumorigenesis, especially in the formation of metastases to peritoneal organs and distant organs. The carcinoma of unknown primary application segment was observed as the fastest-growing market throughout the forecast period of 2016–2024 at a CAGR of 4.1%. According to medical practitioners, the case of an unknown primary with malignant ascites is one of the challenges in the medical field, as due to metastasis, the source of cancer is unknown, and ascites take place due to multiple organ damage caused by cancer. The major factor restraining growth in this segment is a lack of diagnostic technology and medical expertise.
Based on the type of treatment, the malignant ascites market is segmented into:
- Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Surgical treatment accounted for the largest share of the overall market at 57.7% in 2015. However, higher costs of drugs and chemotherapy products are used in malignant ascites treatment, but most of the time, due to late diagnosis, the patient’s situation requires instant relief, which is possible only with the help of surgery. Drugs also form the first line of treatment in ascites management, and in the near future, a strong drug pipeline is expected to provide highly effective drug molecules. The surgical treatment segment will undergo steady market growth in light of the perpetual rise in incidence and the requirement for repeated paracentesis. Catumaxomab is a monoclonal antibody that has been developed to target specific components of cells. It links cancer cells with immune cells, thus enabling the immune system to kill cancer cells. Several prospective studies have presented positive results concerning the efficacy and efficiency of catumaxomab in treating malignant ascites. Market experts suggest that the development of monoclonal technologies and advances in non-invasive cancer treatment research pose a serious challenge to palliative care modes.
For the purpose of this study, the global malignant ascites treatment market is categorized into three segments:
- North America
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
In the base year 2015, North America was observed as the leading geographical region in the malignant ascites market due to the rising prevalence of cancers, developing early diagnosis technologies, high awareness among medical practitioners about the risks involved with ascites, and a strong product pipeline that is expected to provide more treatment options in the near future. Medical practitioners suggest that ovarian cancer has been described as the “silent killer” due to the minimal number of symptoms associated with it at diagnosis. However, for patients who do not suffer from ascites initially but develop them during a disease relapse, it can be the first visible manifestation of their disease. Several published medical studies also suggest that patients with malignant ascites have a poor prognosis, with median overall survival (MOS) varying between 1 and 6 months. Japan was observed as the largest market in Asia-Pacific due to a peaking geriatric population, increasing prevalence of cancers, and high public awareness related to early diagnosis, coupled with several government initiatives that are expected to drive the market throughout the forecast period.